Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030348 · ClinicalTrials.gov registry record
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
A clinical trial of Pancreatic Diseases and Pancreatic Cancers, sponsored by Do Hyun Park.
- Recruiting
- Registry status
- 263
- Enrollment target
- 3
- Study locations
NCT07030348: Recruiting study of Pancreatic Diseases and Pancreatic Cancers, sponsored by Do Hyun Park.
NCT07030348 is a study of Pancreatic Diseases and Pancreatic Cancers that is actively recruiting participants, run by Do Hyun Park. The registered enrollment target is 263 participants, below the 1,136-participant average among 5 other Pancreatic Diseases trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07030348, a study of Pancreatic Diseases and Pancreatic Cancers, is actively recruiting participants, sponsored by Do Hyun Park.
- RECRUITING
- Registry status
- 263 participants
- Enrollment target
- 3
- Study locations
Study Summary
Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.
Primary Outcome
Area Under the Receiver Operating Characteristic Curve (AUC) and 95% Confidence Interval (CI) of candidate biomarkers in the training cohort. If the AUC falls within ±5% of the target value (0.94), the optimal cutoff value for pancreatic cancer differentiation will be reported using Youden's Index.
Conditions Studied
Study Locations (3)
Colorado
- University of Colorado Hospital - Aurora
Ohio
- Cleveland Clinic - Cleveland
Other
- Asan Medical Center - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2026-12-31 |
What NCT07030348 shows while recruiting
NCT07030348 is an observational study that tracks outcomes without assigning an intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 1,136-participant average among 5 other Pancreatic Diseases trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Pancreatic Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT07030348 reports a single indexed study location in Colorado, Ohio, Other.
Frequently Asked Questions
What is clinical trial NCT07030348 about?
NCT07030348 is a clinical study titled "Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study". Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic ca...
What is the current status of trial NCT07030348?
This trial is currently recruiting. The enrollment target is 263 participants. The study started on 2024-01-02. Estimated completion is 2026-12-31.
What conditions does trial NCT07030348 study?
This clinical trial studies the following conditions: Pancreatic Diseases, Pancreatic Cancers.
Who is sponsoring clinical trial NCT07030348?
This trial is sponsored by Do Hyun Park, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07030348 being conducted?
This trial has 3 study locations across Colorado, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
UCSF PANC Cyst Registry
RECRUITING
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
RECRUITING
-
Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
ACTIVE NOT RECRUITING · Phase 2
-
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
COMPLETED · Phase 3
-
Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI